

Form PTO-1449 (MW&E Ver. REV. 7-98)	US Dept. of Commerce PATENT & TRADEMARK OFFICE	ATTY DOCKET NO. 50350-15P E <i>SC 95</i>	APPLICATION NO. 08/913/555
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		MAY 27 1999	
		APPLICANT Kayagaki et al.	PATENT & TRADEMARK OFFICE
		FILING DATE September 19, 1997	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
							/

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION
<i>MA Abstract only</i>		WO 95/27735	10/19/95	PCT			X Abstract

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

<i>MA</i>	<i>✓</i>	"Expression of the functional soluble form of human Fas ligand in activated lymphocytes", Tanaka et al., The EMBO Journal, Vol. 14, No. 6, pp. 1129-1135, March 15, 1995
		"The Fas Death Factor", Nagata et al., Science, Vol. 267, No. 5203, pp. 1449-1456, March 10, 1995
		"Role of Fas Ligand in Apoptosis Induced by Hepatitis C Virus Infection", Mita et al., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATION, Vol. 204, No. 2, pp. 468-474, October 28, 1994
		"Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family", Suda et al., Cell, Vol. 75, pp. 1169-1178, December 17, 1993 <i>Duplicate</i>
		"Continuous cultures of fused cells secreting antibody of predefined specificity", Nature, Vol. 256, pp. 495-497, August 7, 1995 <i>Köhler et al.</i>
		"Metalloproteinase-mediated Release of Human Fas Ligand", Kayagaki et al., J. Exp. Med., Vol. 182, pp. 1777-1783, December 1995.
		Supplemental European Search Report for Application No. 96906907, dated April 8, 1999

EXAMINER

DATE CONSIDERED

*Mary B. Dry**6-8-99*

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.